<p>塔苏斯制药公司（NASDAQ:TARS - 获取免费报告）在周一达到了新的 52 周高点。该公司交易最高达到 83.78 美元，最后交易价格为 82.9950 美元，成交量为 160715 股。该股票此前收盘价为 81.77 美元。</p>
<p>获取 <strong>塔苏斯制药</strong> 的提醒：</p>
<h2>分析师评级变动</h2>
<ul>
<li>3 个生物技术催化剂带来重大机会</li>
</ul>
<p>TARS 已成为几份研究报告的主题。瑞穗证券在 11 月 20 日（星期四）的一份报告中开始覆盖塔苏斯制药。他们为该公司设定了 “跑赢大盘” 的评级和 100.00 美元的目标价。HC Wainwright 在 10 月 20 日（星期一）的一份研究报告中将塔苏斯制药的目标价从 72.00 美元上调至 88.00 美元，并给予该股票 “中性” 评级。古根海姆在 11 月 5 日（星期三）的一份研究报告中将塔苏斯制药的目标价从 84.00 美元上调至 87.00 美元，并给予该公司 “买入” 评级。Weiss Ratings 在 10 月 8 日（星期三）的一份研究报告中重申了对塔苏斯制药的 “卖出（d-）” 评级。最后，华尔街 Zen 在 11 月 8 日（星期六）的一份报告中将塔苏斯制药的评级从 “持有” 上调至 “买入”。六位投资分析师对该股票给予了买入评级，两位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “适度买入”，共识目标价为 74.14 美元。</p>
<p><strong>查看我们关于塔苏斯制药的最新研究报告</strong></p>
<h2>塔苏斯制药的价格表现</h2>
<p>该公司的 50 日简单移动平均线为 72.01 美元，200 日简单移动平均线为 55.67 美元。该公司的债务与股本比率为 0.22，速动比率为 4.25，流动比率为 4.29。该股票的市值为 34.9 亿美元，市盈率为-40.71，贝塔值为 0.74。</p>
<p>塔苏斯制药（NASDAQ:TARS - 获取免费报告）最近在 11 月 4 日（星期二）发布了季度财报。该公司报告每股收益（EPS）为-0.30 美元，超出市场共识预期的-0.35 美元，超出 0.05 美元。该业务的季度收入为 1.187 亿美金，而分析师预期为 1.1422 亿美金。塔苏斯制药的净利润率为-22.17%，股本回报率为-26.29%。作为一个整体，股票研究分析师预计塔苏斯制药公司在当前财政年度将发布-3.17 的每股收益。</p>
<h2>塔苏斯制药的内部活动</h2>
<p>在其他消息中，首席执行官 Bobak R. Azamian 在 9 月 24 日（星期三）出售了 6000 股公司的股票。股票以平均价格 55.37 美元出售，总价值为 332,220.00 美元。出售后，首席执行官直接持有 812,106 股公司股票，价值约为 44,966,309.22 美元。此次交易代表其持股比例减少了 0.73%。该交易已在向 SEC 提交的文件中披露，相关文件可通过此超链接访问。公司内部人士持有公司 8.97% 的股票。</p>
<h2>塔苏斯制药的机构交易</h2>
<p>对冲基金和其他机构投资者最近调整了对该股票的持有。安联资产管理公司在第二季度购买了塔苏斯制药的新股份，价值 227,000 美元。Lisanti Capital Growth LLC 在第二季度将其在塔苏斯制药的股份增加了 7.6%。Lisanti Capital Growth LLC 现在拥有 75,525 股公司股票，价值 3,060,000 美元，此前在上个季度又购买了 5,345 股。Strs Ohio 在第一季度购买了塔苏斯制药的新股份，价值约 288,000 美元。Adage Capital Partners GP L.L.C.在第一季度获得了塔苏斯制药的新职位，价值约 26,199,000 美元。最后，Campbell &amp; CO Investment Adviser LLC 在第二季度获得了塔苏斯制药的新职位，价值约 416,000 美元。机构投资者持有公司 90.01% 的股票。</p>
<h2>关于塔苏斯制药</h2>
<p>（获取免费报告）</p>
<p>塔苏斯制药公司是一家商业阶段的生物制药公司，专注于在美国开发和商业化新型眼科治疗候选药物。该公司的主要产品候选药物是 XDEMVY，一种用于治疗由蠕形螨感染引起的睑板腺炎的新型治疗药物，以及用于治疗睑板腺疾病。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们更看好的股票比塔苏斯制药更好</li>
<li>3 只天然气股票提供优厚的股息收益</li>
<li>5 只内部人士正在出售的科技股（但聪明的投资者正在大量买入）</li>
<li>股票股息削减发生，你准备好了吗？</li>
<li>为什么 FuelCell Energy 的股票在政府交易后飙升</li>
<li>3 只值得长期持有的 REIT</li>
<li>软银的下一个 AI 举动？DigitalBridge 因收购传闻上涨 46%</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在塔苏斯制药吗？</h2>
<p>在你考虑塔苏斯制药之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而塔苏斯制药并不在名单上。</p>
<p>虽然塔苏斯制药目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票的详情</p>

TARS

<p>Tarsus Pharmaceuticals（纳斯达克代码：TARS）达到了新的 52 周高点，交易价格为 83.78 美元。分析师们给出了混合评级，普遍目标价为 74.14 美元。该公司报告的季度收益超出预期，收入为 1.187 亿美金。首席执行官 Bobak Azamian 出售了部分股份，机构投资者持有 90.01% 的股票。Tarsus 专注于眼科治疗，其主打产品 XDEMVY 针对睑板腺炎</p>

<p>Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) reached a new 52-week high on Monday . The company traded as high as $83.78 and last traded at $82.9950, with a volume of 160715 shares. The stock had previously closed at $81.77.</p>
<div class="lb-trans"><p>塔苏斯制药公司（NASDAQ:TARS - 获取免费报告）在周一达到了新的 52 周高点。该公司交易最高达到 83.78 美元，最后交易价格为 82.9950 美元，成交量为 160715 股。该股票此前收盘价为 81.77 美元。</p>
</div><p>Get <strong>Tarsus Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>塔苏斯制药</strong> 的提醒：</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><ul>
<li>3 Biotech Catalysts Present Major Opportunity</li>
</ul>
<div class="lb-trans"><ul>
<li>3 个生物技术催化剂带来重大机会</li>
</ul>
</div><p>TARS has been the subject of several research reports. Mizuho began coverage on Tarsus Pharmaceuticals in a report on Thursday, November 20th. They set an &#34;outperform&#34; rating and a $100.00 price target for the company. HC Wainwright raised their target price on shares of Tarsus Pharmaceuticals from $72.00 to $88.00 and gave the stock a &#34;neutral&#34; rating in a research note on Monday, October 20th. Guggenheim upped their price target on shares of Tarsus Pharmaceuticals from $84.00 to $87.00 and gave the company a &#34;buy&#34; rating in a research note on Wednesday, November 5th. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Tarsus Pharmaceuticals in a research report on Wednesday, October 8th. Finally, Wall Street Zen upgraded Tarsus Pharmaceuticals from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Saturday, November 8th. Six investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $74.14.</p>
<div class="lb-trans"><p>TARS 已成为几份研究报告的主题。瑞穗证券在 11 月 20 日（星期四）的一份报告中开始覆盖塔苏斯制药。他们为该公司设定了 “跑赢大盘” 的评级和 100.00 美元的目标价。HC Wainwright 在 10 月 20 日（星期一）的一份研究报告中将塔苏斯制药的目标价从 72.00 美元上调至 88.00 美元，并给予该股票 “中性” 评级。古根海姆在 11 月 5 日（星期三）的一份研究报告中将塔苏斯制药的目标价从 84.00 美元上调至 87.00 美元，并给予该公司 “买入” 评级。Weiss Ratings 在 10 月 8 日（星期三）的一份研究报告中重申了对塔苏斯制药的 “卖出（d-）” 评级。最后，华尔街 Zen 在 11 月 8 日（星期六）的一份报告中将塔苏斯制药的评级从 “持有” 上调至 “买入”。六位投资分析师对该股票给予了买入评级，两位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “适度买入”，共识目标价为 74.14 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on Tarsus Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我们关于塔苏斯制药的最新研究报告</strong></p>
</div><h2>Tarsus Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>塔苏斯制药的价格表现</h2>
</div><p>The company has a fifty day simple moving average of $72.01 and a two-hundred day simple moving average of $55.67. The company has a debt-to-equity ratio of 0.22, a quick ratio of 4.25 and a current ratio of 4.29. The stock has a market capitalization of $3.49 billion, a price-to-earnings ratio of -40.71 and a beta of 0.74.</p>
<div class="lb-trans"><p>该公司的 50 日简单移动平均线为 72.01 美元，200 日简单移动平均线为 55.67 美元。该公司的债务与股本比率为 0.22，速动比率为 4.25，流动比率为 4.29。该股票的市值为 34.9 亿美元，市盈率为-40.71，贝塔值为 0.74。</p>
</div><p>Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.05. The business had revenue of $118.70 million for the quarter, compared to analyst estimates of $114.22 million. Tarsus Pharmaceuticals had a negative net margin of 22.17% and a negative return on equity of 26.29%. As a group, equities research analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>塔苏斯制药（NASDAQ:TARS - 获取免费报告）最近在 11 月 4 日（星期二）发布了季度财报。该公司报告每股收益（EPS）为-0.30 美元，超出市场共识预期的-0.35 美元，超出 0.05 美元。该业务的季度收入为 1.187 亿美金，而分析师预期为 1.1422 亿美金。塔苏斯制药的净利润率为-22.17%，股本回报率为-26.29%。作为一个整体，股票研究分析师预计塔苏斯制药公司在当前财政年度将发布-3.17 的每股收益。</p>
</div><h2>Insider Activity at Tarsus Pharmaceuticals</h2>
<div class="lb-trans"><h2>塔苏斯制药的内部活动</h2>
</div><p>In other news, CEO Bobak R. Azamian sold 6,000 shares of the firm's stock in a transaction that occurred on Wednesday, September 24th. The shares were sold at an average price of $55.37, for a total value of $332,220.00. Following the sale, the chief executive officer directly owned 812,106 shares in the company, valued at approximately $44,966,309.22. This trade represents a 0.73% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 8.97% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，首席执行官 Bobak R. Azamian 在 9 月 24 日（星期三）出售了 6000 股公司的股票。股票以平均价格 55.37 美元出售，总价值为 332,220.00 美元。出售后，首席执行官直接持有 812,106 股公司股票，价值约为 44,966,309.22 美元。此次交易代表其持股比例减少了 0.73%。该交易已在向 SEC 提交的文件中披露，相关文件可通过此超链接访问。公司内部人士持有公司 8.97% 的股票。</p>
</div><h2>Institutional Trading of Tarsus Pharmaceuticals</h2>
<div class="lb-trans"><h2>塔苏斯制药的机构交易</h2>
</div><p>Hedge funds and other institutional investors have recently modified their holdings of the stock. Allianz Asset Management GmbH bought a new stake in Tarsus Pharmaceuticals during the 2nd quarter worth $227,000. Lisanti Capital Growth LLC boosted its stake in shares of Tarsus Pharmaceuticals by 7.6% during the second quarter. Lisanti Capital Growth LLC now owns 75,525 shares of the company's stock valued at $3,060,000 after purchasing an additional 5,345 shares in the last quarter. Strs Ohio bought a new stake in shares of Tarsus Pharmaceuticals during the first quarter worth about $288,000. Adage Capital Partners GP L.L.C. acquired a new position in shares of Tarsus Pharmaceuticals in the first quarter valued at approximately $26,199,000. Finally, Campbell &amp; CO Investment Adviser LLC acquired a new position in shares of Tarsus Pharmaceuticals in the second quarter valued at approximately $416,000. Institutional investors own 90.01% of the company's stock.</p>
<div class="lb-trans"><p>对冲基金和其他机构投资者最近调整了对该股票的持有。安联资产管理公司在第二季度购买了塔苏斯制药的新股份，价值 227,000 美元。Lisanti Capital Growth LLC 在第二季度将其在塔苏斯制药的股份增加了 7.6%。Lisanti Capital Growth LLC 现在拥有 75,525 股公司股票，价值 3,060,000 美元，此前在上个季度又购买了 5,345 股。Strs Ohio 在第一季度购买了塔苏斯制药的新股份，价值约 288,000 美元。Adage Capital Partners GP L.L.C.在第一季度获得了塔苏斯制药的新职位，价值约 26,199,000 美元。最后，Campbell &amp; CO Investment Adviser LLC 在第二季度获得了塔苏斯制药的新职位，价值约 416,000 美元。机构投资者持有公司 90.01% 的股票。</p>
</div><h2>About Tarsus Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于塔苏斯制药</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.</p>
<div class="lb-trans"><p>塔苏斯制药公司是一家商业阶段的生物制药公司，专注于在美国开发和商业化新型眼科治疗候选药物。该公司的主要产品候选药物是 XDEMVY，一种用于治疗由蠕形螨感染引起的睑板腺炎的新型治疗药物，以及用于治疗睑板腺疾病。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Tarsus Pharmaceuticals</li>
<li>3 Natural Gas Stocks That Offer Great Dividend Yields</li>
<li>5 Tech Stocks Insiders Are Selling (But Smart Investors Are Loading Up)</li>
<li>Stock Dividend Cuts Happen Are You Ready?</li>
<li>Why FuelCell Energy Stock Is Soaring After a Government Deal</li>
<li>3 REITs to Buy and Hold for the Long Term</li>
<li>SoftBank’s Next AI Move? DigitalBridge Rockets 46% on Takeover Buzz</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票比塔苏斯制药更好</li>
<li>3 只天然气股票提供优厚的股息收益</li>
<li>5 只内部人士正在出售的科技股（但聪明的投资者正在大量买入）</li>
<li>股票股息削减发生，你准备好了吗？</li>
<li>为什么 FuelCell Energy 的股票在政府交易后飙升</li>
<li>3 只值得长期持有的 REIT</li>
<li>软银的下一个 AI 举动？DigitalBridge 因收购传闻上涨 46%</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Tarsus Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在塔苏斯制药吗？</h2>
</div><p>Before you consider Tarsus Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑塔苏斯制药之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tarsus Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而塔苏斯制药并不在名单上。</p>
</div><p>While Tarsus Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然塔苏斯制药目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票的详情</p>
</div>

Tarsus Pharmaceuticals（NASDAQ:TARS）创下新的 12 个月高点 - 发生了什么